Search clinical trials for: intermediate risk

Total 15889 results

Daniel George, MD
Merck Sharp & Dohme LLC

Not yet recruiting

Trimodality Approach of Low Dose iOnizing Radiation With or Without Neoadjuvant Pembrolizumab and Prostatectomy for Men With Intermediate/High Risk Prostate Cancer (TALON) (TALON)

Prostate Cancer

United States
Shanghai Ninth People's Hospital Affiliated to...
Fudan University; First Affiliated Hospital of Fujian Medical University; Tianjin... and other collaborators

Recruiting

Concurrent Immunotherapy With Postoperative Radiotherapy in Intermediate/High Risk HNSCC Patients Unfit for Cisplatin: The IMPORT Study (IMPORT) (IMPORT)

Head and Neck Squamous Cell Carcinoma

China
David Büchser

Recruiting

HDR Brachytherapy Plus Stereotactic Ablative Prostate Radiotherapy for Patients With Intermediate and High-risk Prostate Cancer (BRAchySABR)

Prostatic Neoplasm

Spain
University of Athens

Recruiting

TAVI in Intermediate Risk Septuagenarians With Risk Factors Not Captured by the Traditional Surgical Risk Scores

Transcatheter Aortic Valve Replacement

Greece
Ruijin Hospital

Recruiting

Evaluating Omitting of Internal Mammary Irradiation Among Early Stage Intermediate Risk (N1) Breast Cancer

Breast Cancer

China
Poznan University of Medical Sciences

Recruiting

Catheter-directed Thrombectomy in High and Intermediate-high Risk Pulmonary Embolism (CATH-PE)

Pulmonary Embolism With Acute Cor Pulmonale

Poland
University of Virginia

Recruiting

EBRT and HDR Brachytherapy for Unfavorable-intermediate, High, and Very High-risk Prostate Cancer (Prostate005)

Prostate Cancer | Prostate Adenocarcinoma

United States
Azienda Ospedaliero-Universitaria di Modena

Recruiting

Evaluation of Diagnostic Accuracy of [68Ga]Ga-PSMA-11 PET/CT in Primary Staging of Intermediate and High Risk Prostatic Cancer in Men Newly Diagnosed (PSMA-PROSTAPET)

Neoplasms | Urogenital Neoplasms | Disease Attributes | Prostate Cancer | Prostatic Neoplasm | Prostatic Disease

Italy
Yonsei University

Recruiting

The Efficacy and Safety of Non-vItamiN K antaGonist oraL Anticoagulants for intermEdiate Stroke Risk in Patients With Atrial Fibrillation (SINGLE-AF)

Atrial Fibrillation Patients With Intermediate Stroke Risk

Korea, Republic of
Assistance Publique - Hôpitaux de Paris
Canadian Institutes of Health Research (CIHR); Boehringer Ingelheim; Johannes... and other collaborators

Recruiting

Pulmonary Embolism International THrOmbolysis Study-3 (PEITHO-3)

Pulmonary Embolism

Netherlands, Spain, Belgium, Slovenia, France, Portugal, Austria, Canada, Poland, Switzerland, Germany, Italy, Romania, Serbia
Keros Therapeutics, Inc.

Recruiting

A Study of KER-050 to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes

Myelodysplastic Syndromes | Cytopenia

Australia, Spain, United States, Israel, France, Germany, New Zealand, Czechia
Weill Medical College of Cornell University
National Cancer Institute (NCI)

Recruiting

Study of PSMA PET/MR Guided Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost (SBRT-SIB) for High-Intermediate and High Risk Prostate Cancer (PSMA SBRT-SIB)

Prostate Cancer

United States
Dan Zandberg
Merck Sharp & Dohme LLC; ISA Pharmaceuticals

Recruiting

HPV-16 Vaccination and Pembrolizumab Plus Cisplatin for "Intermediate Risk" HPV-16-associated Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma | HPV-Related Squamous Cell Carcinoma

United States
Zhujiang Hospital

Recruiting

Treatment Efficacy and Safety of Low-dose Radioiodine Ablation for Intermediate-risk Differentiated Thyroid Carcinoma

Papillary Thyroid Cancer

China
Centre Francois Baclesse
French cancer Institute INCa

Recruiting

Systematic Radioiodine Administration Versus Decision of Radioiodine Treatment Guided by a Post-operative Work-up (INTERMEDIATE)

Thyroid Cancer | Intermediate Risk

France
University Health Network, Toronto
Bayer; Prostate Cancer Canada

Not yet recruiting

Study of Radiation Therapy in Combination With Darolutamide + Degarelix in Intermediate Risk Prostate Cancer (SChLAP/IDC)

Prostate Cancer

Canada
Gruppo Italiano Malattie EMatologiche dell'Adulto

Recruiting

Gemtuzumab Chemotherapy MRD Levels; Glasdegib Post-transplant, Adult Untreated, de Novo, Fav Interm Risk AML

Acute Myeloid Leukemia

Italy
University of Birmingham
AstraZeneca; Cancer Trials Ireland

Recruiting

CompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC) (CompARE)

Oropharyngeal Cancer

United Kingdom, Ireland
Rigshospitalet, Denmark
University Hospital Bispebjerg and Frederiksberg; Hillerod Hospital, Denmark; Herlev and Gentofte Hospital and other collaborators

Recruiting

Low Dose Thrombolysis, Ultrasound Assisted Thrombolysis or Heparin for Intermediate High Risk Pulmonary Embolism (STRATIFY)

Pulmonary Embolism

Denmark
West German Study Group
Novartis; Genomic Health®, Inc.

Recruiting

Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC (ADAPTcycle)

Breast Cancer Female

Germany
University of Rome Tor Vergata

Recruiting

Focal Laser Ablation for the Treatment of Focal Low-Intermediate Risk Prostate Cancer

Prostate Cancer

Italy
Dana-Farber Cancer Institute
Bayer; Decipher Biosciences

Recruiting

INTREPId (INTermediate Risk Erection PreservatIon Trial)

Prostate Cancer

United States
Children's Oncology Group
National Cancer Institute (NCI)

Recruiting

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

B Acute Lymphoblastic Leukemia | Central Nervous System Leukemia | Testicular Leukemia | B Lymphoblastic Lymphoma | Mixed Phenotype Acute Leukemia

United States, Canada, Australia, Puerto Rico, New Zealand
Sidney Kimmel Comprehensive Cancer Center at Johns...
Incyte Corporation

Recruiting

A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors

Bladder Cancer | NMIBC | Urothelial Carcinoma Recurrent | Non-Muscle Invasive Bladder Cancer

United States
Center Eugene Marquis

Recruiting

Erectile Dysfunction in Good Prognosis Prostate Cancer : Comparison Between Brachytherapy and Stereotactic Body Radiotherapy (TEMPOS)

Prostate Cancer

France
Gruppo Italiano Malattie EMatologiche dell'Adulto

Recruiting

Long-term Safety Study of Arsenic Trioxide in Newly Diagnosed, Low-to-intermediate Risk Acute Promyelocytic Leukemia (APL0618)

Acute Promyelocytic Leukemia

Italy
EBG MedAustron GmbH

Recruiting

Spot-Scanning Based Hypofractionated Proton Therapy for Low and Intermediate Risk Prostate Cancer

Low Risk Prostate Cancer | Intermediate Risk Prostate Cancer

Austria
University Hospital, Bordeaux

Recruiting

68Ga-RM2 Compared to 68Ga-PSMA-617 PET/CT for Intermediate Risk Prostate Cancer Imaging (PROSTATEP)

Prostate Cancer

France
H. Lee Moffitt Cancer Center and Research Institute
James and Esther King Biomedical Research Program

Recruiting

Phase II Trial to Modulate Intermediate Endpoint Biomarkers in Former and Current Smokers

Lung Diseases | Lung Cancer, Protection Against

United States
Hospital JP Garrahan
Hospital Pereyra Rosell, Montevideo, Uruguay

Recruiting

Pediatric Hodgkin Lymphoma Treatment Trial With Low Cumulative Doses of Chemotherapy Agents and Reduced Radiation. (LHGALOP2017)

Pediatric Hodgkin's Disease

Argentina
British Columbia Cancer Agency
BC Cancer Foundation

Recruiting

LDR vs. HDR Brachytherapy for Prostate Cancer (LDR/HDRmono)

Prostate Cancer

Canada
Xuejie Jiang

Recruiting

A Clinical Trail of Demethylation Drug Combined With Chemotherapy in Intermediate-risk AML

Leukemia, Myeloid

China
Centre Georges Francois Leclerc

Recruiting

Study Evaluating the Efficacy and the Tolerance of Pelvic-prostatic Hypo-fractionated Radiotherapy Followed by Boost in Patients With Prostate Adenocarcinoma Adverse Intermediate Risk or High Localized Risk (SHORT)

To Evaluate the Rate of Digestive and Urinary Toxicity

France
Peking University People's Hospital

Recruiting

RIC Regimen for Low- and Intermediate-risk MDS Receiving Haplo-HSCT

Myelodysplastic Syndromes

China
China National Center for Cardiovascular Diseases

Not yet recruiting

The Safety and Effectiveness of Transcatheter Aortic Valve Raplacemet in Intermediate Risk Patients With Bicuspid Aortic Stenosis

Aortic Valve Disease
BioLite, Inc.

Not yet recruiting

A Study of BLEX 404 Oral Liquid in Patients With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-Risk Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML)

Myelodysplastic Syndrome (MDS)
Fundación Instituto Valenciano de Oncología

Recruiting

Spanish Urological Association Registry of Patients on Active Surveillance

Prostate Cancer

Spain
University Hospital, Grenoble

Recruiting

Comparing Sequential Neoadjuvant Treatment Including Chemotherapy and Accelerated Radiation Focused to the Tumor Bed vs Neoadjuvant Chemotherapy Alone (Néo-APBI-01)

Radiation Therapy, Breast Cancer, Sequential Partial Breast Irradiation | Intermediate and High-risk Luminal and Triple Negative Breast Cancer

France
UMC Utrecht
National University Hospital, Singapore; Berry Consultants; University of Pittsburgh... and other collaborators

Recruiting

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (REMAP-CAP)

Community-acquired Pneumonia, Influenza, COVID-19

United Kingdom, United States, Canada, Australia, Netherlands, Croatia, Germany, Belgium, New Zealand, Ireland, Spain, Japan, Hungary, Colombia, India, Nepal, Pakistan, Portugal, Romania, Saudi Arabia
University of Sydney
Dana-Farber Cancer Institute; University of Southern California; Cambridge University... and other collaborators

Recruiting

Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours (P3BEP)

Germ Cell Tumor

Australia, New Zealand, United States
Provision Center for Proton Therapy
Center for Biomedical Research, LLC

Recruiting

Hypofractionated Image Guided Proton Therapy for Low andIntermediate Risk Prostate Cancer

Prostate Cancer

United States
Advocate Health Care

Recruiting

CyberKnife® as Monotherapy or Boost SBRT for Intermediate or High Risk Localized Prostate Cancer

Prostate Adenocarcinoma

United States
Razor Genomics
Encore Clinical

Recruiting

Adjuvant Chemotherapy in Patients With Intermediate or High Risk Stage I or Stage IIA Non-squamous Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer

United States, France, Germany
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome

Previously Treated Myelodysplastic Syndrome | Myelodysplastic Syndrome | Aplastic Anemia | de Novo Myelodysplastic Syndrome

United States
Proton Collaborative Group

Recruiting

Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer

Prostate Cancer

United States
Moscow City Oncology Hospital No. 62

Completed

[SENTRY] Tailoring Postoperative Management Through Sentinel Lymph Node Biopsy in Low- and Intermediate-Risk Endometrial Cancer (SENTRY)

Endometrial Neoplasms | Endometrial Cancer | Sentinel Lymph Node | Endometrial Endometrioid Adenocarcinoma | Endometrial Adenocarcinoma | Hysterectomy | Endometrial Cancer Stage I | Laparoscopic Hysterectomy | Endometrial Cancer Stage II

Russian Federation
Karyopharm Therapeutics Inc

Active, not recruiting

Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications

Acute Myeloid Leukemia (AML) | Metastatic Colorectal Cancer (mCRC) | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Relapsed/Refractory Multiple Myeloma (RRMM) | Higher-Risk Myelodysplastic Syndrome (HR-MDS) | Newly Diagnosed Intermediate/High-Risk MDS

United States, France, Canada, Spain, China
University of Leipzig
Curis, Inc.

Terminated

Treatment of Anemia in Patients With Very Low, Low or Intermediate Risk Myelodysplastic Syndromes With CA-4948 (LUCAS)

Myelodysplastic Syndromes | Anemia

Germany
Astex Pharmaceuticals, Inc.

Terminated

A Study of Oral Decitabine/Cedazuridine in Combination With Magrolimab in Participants With Intermediate- to Very High-Risk Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes

United States
Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) (STIMULUS-MDS2)

Myelodysplastic Syndromes | Leukemia, Myelomonocytic, Chronic

China, Czechia, Japan, Saudi Arabia, Taiwan, Turkey, Germany, Spain, Netherlands, Italy, Singapore, Australia, Austria, France, United Kingdom, Korea, Republic of, Thailand, Israel, Belgium, Canada, Switzerland, Lithuania, Russian Federation and more

Search clinical trials for: intermediate risk

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations